PRLD 8-K: SEC filing

Filed with the SEC on · accession 0001193125-26-462029

PRLD filed a 8-K (current report) with the SEC on Nov 16, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Prelude Therapeutics furnished its Q3 2026 financial results via a press release and provided investor presentation materials under Regulation FD disclosure.

Key details

RegistrantPrelude Therapeutics Incorporated
Chief financial officer and chief legal officerBryant Lim

✦ Ask GOAX AI about this filing — what it means for PRLD, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PRLD?

Click here

Frequently asked questions

What did PRLD file with the SEC on Nov 16, 2026?

PRLD filed a 8-K (SEC filing). Prelude Therapeutics furnished its Q3 2026 financial results via a press release and provided investor presentation materials under Regulation FD disclosure.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other PRLD SEC filings

Get alerts when PRLD files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days